EG 427 presents positive preclinical data on lead asset EG110A at International Continence Society meeting

September 13, 2023

EG 427 announces today on oral presentation of preclinical data on its lead asset EG110A, a novel non-replicative herpes simplex virus Type 1 (HSV1)-derived vector expressing the light chain of botulinum toxin F, at the International Continence Society’s annual meeting (ICS 2023), being held September 27-29, 2023 in Toronto, Canada 

Read Full Press Release in English or in French

Details of the oral presentation: 

Title: Intravesical administration of EG110A, a novel non-replicative herpes simplex virus Type 1 (HSV1)- derived vector expressing the light chain of botulinum toxin F, inhibits C-type fibers in an acute intravesical capsaicin rat model 

Session S13: Pelvic pain and inflammation
Time: September 28, 2023 – 9am (local time)
Location: Toronto, Canada
Presenting: Julien Ratelade, preclinical project manager at EG 427 

For the full abstract, please click here. 

---